Utility of Presepsin and Interferon-λ3 for Predicting Disease Severity and Clinical Outcomes in COVID-19 Patients
by
, , , , , and
Gun-Hyuk Lee
1
,
Mikyoung Park
2,
Mina Hur
1,*
,
Hanah Kim
1,
Seungho Lee
3
,
Hee-Won Moon
1 and
Yeo-Min Yun
1 1
Department of Laboratory Medicine, Konkuk University School of Medicine, Konkuk University Medical Center, 120-1, Neungdong-ro, Hwayang-dong, Gwangjin-gu, Seoul 05030, Republic of Korea
2
Department of Laboratory Medicine, Eunpyeong St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 03312, Republic of Korea
3
Department of Preventive Medicine, College of Medicine, Dong-A University, Busan 49201, Republic of Korea
*
Author to whom correspondence should be addressed.
Diagnostics 2023, 13(14), 2372; https://doi.org/10.3390/diagnostics13142372
Submission received: 15 June 2023
/
Revised: 11 July 2023
/
Accepted: 13 July 2023
/
Published: 14 July 2023
(This article belongs to the Section Clinical Laboratory Medicine)
Abstract
:We explored the utility of novel biomarkers, presepsin and interferon-λ3 (IFN-λ3), for predicting disease severity and clinical outcomes in hospitalized Coronavirus (COVID-19) patients. In a total of 55 patients (non-critical, n = 16; critical, n = 39), presepsin and IFN-λ3 were compared with sequential organ failure assessment (SOFA) scores and age. Disease severity and clinical outcomes (in-hospital mortality, intensive care unit admission, ventilator use, and kidney replacement therapy) were analyzed using receiver operating characteristic (ROC) curves. In-hospital mortality was also analyzed using the Kaplan-Meier method with hazard ratios (HR). SOFA scores, age, presepsin, and IFN-λ3 predicted disease severity comparably (area under the curve [AUC], 0.67–0.73). SOFA score and IFN-λ3 predicted clinical outcomes comparably (AUC, 0.68–0.88 and 0.66–0.74, respectively). Presepsin predicted in-hospital mortality (AUC = 0.74). The combination of presepsin and IFN-λ3 showed a higher mortality risk than SOFA score or age (HR [95% confidence interval, CI], 6.7 [1.8–24.1]; 3.6 [1.1–12.1]; 2.8 [0.8–9.6], respectively) and mortality rate further increased when presepsin and IFN-λ3 were added to SOFA scores or age (8.5 [6.8–24.6], 4.2 [0.9–20.6], respectively). In the elderly (≥65 years), in-hospital mortality rate was significantly higher when both presepsin and IFN-λ3 levels increased than when either one or no biomarker level increased (88.9% vs. 14.3%, p < 0.001). Presepsin and IFN-λ3 predicted disease severity and clinical outcomes in hospitalized COVID-19 patients. Both biomarkers, whether alone or added to the clinical assessment, could be useful for managing COVID-19 patients, especially the elderly.
1. Introduction
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as Coronavirus disease 2019 (COVID-19), outbroke in December 2019. There have been over 765 million cases and 6.9 million deaths worldwide as of 10 May 2023 [1]. Globally, elderly patients aged 65 years or older account for a strikingly higher proportion of COVID-19 deaths (81.0–86.2%), and the mortality rate differed remarkably between the young and the elderly. Compared with patients aged 54 years or younger, the incident rate ratio (IRR) of elderly patients was 62 (95% confidence interval [CI], 59.7–64.7), indicating that the mortality rate of the elderly was 62 times higher than younger patients in cases of COVID-19 [2,3].
COVID-19 patients show heterogenous disease courses ranging from no symptoms to critical illness. The World Health Organization (WHO) stratified COVID-19 severity into four categories: mild, moderate, severe, and critical disease, and sepsis is included in the critical disease category [4]. COVID-19 induces significant changes in the host’s immune response, and sepsis has been observed in nearly all COVID-19 related deaths [5]. Accordingly, the sequential organ failure assessment (SOFA) score that is essential for the diagnosis of sepsis has been also used to predict COVID-19 severity and clinical outcomes [6,7]. COVID-19 patients that have higher SOFA scores and lymphocytopenia upon hospital admission showed a greater risk of developing severe diseases [7]. Along with the SOFA score, several clinical assessment tools have been applied to predict COVID-19 severity and clinical outcomes, including a COVID-19 severity index (CSI), Coronavirus clinical characterization consortium (4C) mortality score, and Veteran’s Health Administration COVID-19 (VACO) index [8,9,10,11]. CSI was developed based on the National Early Warning Score 2 (NEWS-2) for predicting COVID-19 severity in hospitalized patients and showed better capacity for predicting intensive care unit (ICU) admission than NEWS-2 [11].
In addition to the clinical assessments, many conventional and emerging biomarkers have been explored in COVID-19 patients, and biomarkers, alone or added to clinical assessments, are effective options for predicting COVID-19 severity and clinical outcomes [12,13,14,15,16]. Presepsin, a soluble cluster of differentiation 14 subtype (sCD14-ST), is released into circulation by pro-inflammatory signals during infection, and its diagnostic and prognostic utility has been proven in sepsis. Presepsin is also useful for predicting COVID-19 severity and mortality (both in-hospital and 30-day) [13,16,17,18,19]. Interferons (IFNs) are potent multifunctional cytokines secreted by various cell types. COVID-19 blocks type I and III IFN responses by inhibiting innate recognition of the virus, the production of IFNs, and the IFN signaling pathway [20,21,22]. In COVID-19, IFN-λ3 levels surged and dropped suddenly before developing severe disease; IFN-λ3 levels were significantly higher in severe and critical diseases than in mild or moderate diseases and could predict oxygen requirements [23,24].
In this study, we explored the clinical utility of both presepsin and IFN-λ3 for predicting disease severity and adverse clinical outcomes in hospitalized COVID-19 patients. We hypothesized that combined use of these biomarkers or biomarkers added to clinical assessments would be more effective than using the clinical assessment tool alone. We also hypothesized that such an approach might help further stratify disease severity and risk of adverse clinical outcomes even in the same age group, and especially in the elderly.
2. Materials and Methods
2.1. Study Population
The study population was a total of 55 COVID-19 patients who were admitted to the Konkuk University Medical Center (KUMC), in Seoul, Republic of Korea, from June 2020 to June 2021. They consisted of 30 men and 25 women, and their median age was 72 years (interquartile range [IQR], 61–80 years). The study population had no specific limitations on care at enrollment, and biomarker testing was conducted at enrollment (IQR, 0–1 day). In all patients, remaining samples were collected following routine blood testing, and no additional intervention or blood sampling was performed. Their medical records were reviewed retrospectively for clinical and laboratory findings. The study protocol was approved by the institutional review board of KUMC (approval No. 2021-04-048), and obtaining written informed consent from the study population was waived.
In all patients, the diagnosis of COVID-19 was confirmed via real-time reverse transcription-polymerase chain reaction (RT-PCR) [25]. The Real-Q 2019-nCoV assay (BioSewoom, Seoul, Republic of Korea) with Real-Q 2019-nCoV Detection kits using nasopharyngeal swabs were used, and a positive result was defined as threshold cycle values of ≤38 for the target genes (E and RdRP), according to the manufacturer’s instructions [25].
Table 1 shows the demographic, clinical, and laboratory findings of the study population. The SOFA scores and CSI were assessed at enrollment together with biomarker testing. Sepsis or septic shock was defined, according to the Sepsis-3 definition [7]. The CSI uses parameters that are scored from 0 to 3 each, and sum of the scored parameters was used to stratify COVID-19 severity (low [0–2], moderate [3–5], high [6–7], and critical [>7]). Parameters used include age, gender, comorbidities (heart failure, chronic obstructive pulmonary disease [COPD], and diabetes with end-organ damage), chest radiography, respiratory rate, pulse oximeter oxygen saturation on room air (SpO2 or SpO2 in COPD), need of oxygen support, symptoms of dyspnea, D-dimer, lymphocytes, and platelets. Chest radiography was evaluated on admission, but it was reconsidered when a new one was performed. If laboratory test results were available 48 h after admission, they were not considered [12]. According to the CSI, the study population was divided into non-critical (n = 16; low, n = 3; moderate, n = 11; high, n = 2) and critical (n = 39) diseases.
2.2. Presepsin and IFN-λ3 Assays
Residual sera were aliquoted to avoid repeated freezing and thawing and were stored at −70 °C until use. Frozen samples were thawed at room temperature and gently mixed immediately before measuring the presepsin and IFN-λ3 levels. Presepsin and IFN- λ3 levels were measured using the two in vitro diagnostics (IVD) assays, an HISCL Presepsin assay and an HISCL IFN-λ3 assay (Sysmex, Kobe, Japan), with HISCL 5000 automated analyzer (Sysmex), respectively. The HISCL Presepsin assay is based on a delayed one-step sandwich chemiluminescence enzyme immunoassay (CLEIA), and the manufacturer-suggested measurement range was 20 to 30,000 pg/mL [26,27]. The HISCL IFN-λ3 assay is based on two-step sandwich CLEIA, and the manufacturer-suggested measurement range was 3 to 200 pg/mL [23,28]. Both assays were performed according to the manufacturer’s instructions.
2.3. Statistical Analysis
Data are presented as a number (percentage) or median (IQR). The Mann–Whitney U test and Fisher’s exact test were used to compare the demographic variables, clinical outcomes, and laboratory data between non-critical (n = 16) and critical (n = 39) diseases. The distribution of presepsin and IFN-λ3 are presented for the purpose of assessing the normality and detecting outliers using the Shapiro–Wilk test and Grubb’s test. Receiver operating characteristic (ROC) curves were analyzed for the purpose of predicting disease severity and clinical outcomes, and the area under the curve (AUC) and optimal cut-off values were estimated. 95% CI of AUC was calculated using the Mann-Whitney (MW) statistic approach, which has been suggested to be superior to other approaches for a small sample size. In a previous study, the MW statistic approach showed coverage probabilities close to the parametric approach of 95% CIs in small sample size [29]. SOFA scores, presepsin, IFN-λ3, and age were explored for predicting disease severity according to the COVID-19 severity index. AUC was interpreted as follows: 0.5 ≤ AUC < 0.6, poor; 0.6 ≤ AUC < 0.7, sufficient; 0.7 ≤ AUC < 0.8, good; 0.8 ≤ AUC < 0.9, very good; AUC ≥ 0.9, excellent [30]. AUC differences and p values were used to compare the discriminative ability of different models. In addition, the indicators were analyzed to find the optimal cut-off for predicting adverse clinical outcomes (in-hospital mortality, ICU admission, ventilator use, and kidney replacement therapy [KRT]). Next, the Kaplan-Meier survival analysis was performed, and using the optimal cut-off values, the hazard ratios (HR, 95% CI) of the SOFA score, presepsin, IFN-λ3, and age were obtained to compare the relative risk for predicting in-hospital mortality. The sample size for the Kaplan-Meier survival analysis was estimated based on a previous study [31]. The inputs were as follows: analysis time t = 2 months, accrual time α = 13 months, follow-up time b = 1 month, null survival probability, S0(t) = 0.013, 0.025, or 0.026, type I error rate (α) = 0.05, and the power (1 − β) = 0.8 [13]. The alternative survival probability was set to S1(t) = 0.236 based on the in-hospital mortality rate of this study. Using log-minus-log transformation that was suggested for improving accuracy in a small sample size, the estimated sample size was 11 to 15. Accordingly, the sample size of 55 was considered sufficient to perform the Kaplan-Meier survival analysis. Lastly, the in-hospital mortality rate based on the optimal cut-off values was compared according to the presepsin and IFN-λ3 by adjusting the age to over 65 years. For the statistical analyses, MedCalc Software (version 20.014, MedCalc Software, Ostend, Belgium) and R version 4.1.0 (The R Foundation for Statistical Computing, Vienna, Austria) were used. p < 0.05 was considered statistically significant.
3. Results
In the study population, sepsis or septic shock was observed in 34 patients (61.8%), with a proportion of 43.7% (n = 7) in non-critical disease patients and 69.2% (n = 27) in critical disease patients. Age, heart rate, respiratory rate, PaO2/FiO2, SOFA score, lymphocyte, blood urea nitrogen, creatinine, presepsin, IFN-λ3, C-reactive protein, prothrombin time, and activated partial thromboplastin time showed significant differences between non-critical and critical diseases (Table 1). Regarding the age, the proportion of elderly patients showed no significant difference between non-critical and critical diseases (p = 0.115).
Presepsin levels differed significantly between non-critical and critical diseases: 282 pg/mL (175–579 pg/mL) in the non-critical disease group vs. 558 pg/mL (402–1232 pg/mL) in the critical disease group (p = 0.008). IFN-λ3 levels also differed significantly between the two groups: 3.0 pg/mL (3.0–3.7 pg/mL) in the non-critical disease group vs. 6.9 pg/mL (3.0–13.8 pg/mL) in the critical disease group (p = 0.049) (Table 1 and Figure 1). In the ROC curve analysis, SOFA scores, presepsin, IFN-λ3, and age demonstrated sufficient to good performances for predicting disease severity (AUC = 0.67–0.73), and their performances were comparable to one another (Figure 2).
For predicting adverse clinical outcomes, SOFA scores and IFN-λ3 levels were comparable. SOFA scores demonstrated sufficient to very good performance (AUC = 0.68–0.88), and IFN-λ3 levels demonstrated sufficient to good performance (AUC = 0.66–0.74). On the contrary, presepsin levels demonstrated good performance (AUC = 0.74) only for in-hospital mortality, and age showed sufficient to very good performances (AUC = 0.66–0.83), except in cases of KRT. SOFA scores were superior to presepsin levels and age for predicting ventilator use (Figure 3). In the Kaplan-Meier analysis, HR (95% CI) for predicting in-hospital mortality was 3.6 (1.1–12.1) for SOFA scores, 6.7 (1.8–24.1) for presepsin and IFN-λ3, 2.8 (0.8–9.6) for age, 8.5 (6.8–24.6) for SOFA scores and presepsin + IFN-λ3, and 4.2 (0.9–20.6) for age and presepsin + IFN-λ3 (Figure 4).
Regarding mortality rates, the mortality rate was 23.6% (13/55) in the total patients and differed significantly according to biomarker levels. It was significantly higher when both presepsin and IFN-λ3 levels increased above optimal cut-offs than when either one or no biomarker level increased (81.8% vs. 9.1%, p < 0.001). The elderly patients accounted for 67.3% (37/55) of the total patients and 92.3% (12/13) of overall deaths. The mortality rate was 32.4% (12/37) in elderly patients. Similar to the total patients, the mortality rate was significantly higher when both presepsin and IFN-λ3 levels increased than when either one or no biomarker level increased (88.9% vs. 14.3%, p < 0.001) (Table 2).
4. Discussion and Conclusions
To the best of our knowledge, this is the first study that explored the clinical utility of two novel biomarkers, presepsin and IFN-λ3, compared with clinical assessments in hospitalized COVID-19 patients. In the present study, among the 55 COVID-19 patients, 16 (39.1%) patients belonged to the non-critical disease group and 39 (70.9%) patients belonged to the critical disease group [11]. Sepsis or septic shock was observed in 34 (61.8%) patients (n = 7, non-critical disease; n = 27, critical disease) (Table 1) [6].
In COVID-19, monocytes are the principal players in orchestrating the host’s immune response; thus, it can be expected that presepsin, which is secreted by monocytes, may have clinical utility in COVID-19 patients [5]. IFN-λ3 is a part of type III IFNs (IFN-λ1 [IL-29], -λ2 [IL-28A], -λ3 [IL-28B], and -λ4), which are structurally related to IL-10 family cytokines. In particular, type I and III IFNs may play crucial roles in innate immune responses [20,21,22]. In the present study, both presepsin and IFN-λ3 levels showed significant differences according to COVID-19 severity (Figure 1). The presepsin level was nearly 2-fold higher (mean difference of 276 pg/mL) and the IFN-λ3 level was nearly 2.5-fold higher (mean difference of 3.9 pg/mL) in the critical disease group than in the non-critical disease group. Our findings are in line with previous findings on each biomarker [13,16,17,18,23,24]. Of note, both presepsin and IFN-λ3 were comparable to SOFA scores and age for predicting disease severity (Figure 2); this finding implies that both biomarkers can be objective and reliable indicators in assessing the clinical status of COVID-19 patients.
Both SOFA scores and age demonstrated sufficient to very good performances (AUC = 0.68–0.88 and AUC = 0.66–0.83, respectively) for predicting all adverse clinical outcomes, with the exception of KRT (Figure 3). Among the two biomarkers, the IFN-λ3 level was comparable to SOFA scores for predicting adverse clinical outcomes (AUC = 0.66–0.74), although the presepsin level demonstrated good performance (AUC = 0.74) only for in-hospital mortality. Our findings support previous studies that demonstrated the clinical utility of presepsin for predicting disease severity and mortality (both in-hospital and 30-day) in critically ill patients [13,16,17,18,19]. Considering that the labeling and interpretation of AUC values may be arbitrary and the clinical usefulness of the discriminating ability of AUC values should be assessed using other tools including net benefit, further studies are warranted [32].
It was also noteworthy that, in the survival analysis, the combination of presepsin and IFN-λ3 showed higher HR (6.7; CI, 1.8–24.1) than SOFA scores (3.6, 1.1–12.1) or age (2.8, 0.8–9.6). This suggests that the combination of these biomarkers could be useful for predicting in-hospital mortality compared with clinical assessments such as SOFA scores. Due to the fact that biomarkers can be measured early at admission, they have advantages over clinical assessments and scoring systems that are difficult to calculate and take some time to evaluate [33,34]. Our data also highlighted that these biomarkers showed greater risk of mortality when added to clinical assessments or age (HR [95% CI], SOFA scores and presepsin and IFN-λ3, 8.5 [6.8–24.6]; age and presepsin and IFN-λ3, 4.2 [0.9–20.6]) (Figure 4).
We further compared in-hospital mortality rates according to biomarker levels (Table 2). Since elderly patients account for a significant proportion of deaths, it is important to stratify risk of in-hospital mortality rates in that age group [2,3]. Considering the high rate of comorbidities in elderly patients, there is a considerable need to investigate the clinical risk and aggressiveness of COVID-19 in these patients [35]. Our data also showed a significantly higher median age in the critical group than in the non-critical group and a higher mortality rate in the elderly patients than in the total patients (32.4% vs. 23.6%); among the 13 non-survivors, except for one patient, the other 12 patients were all elderly patients. In our study population, when both presepsin and IFN-λ3 levels increased above the optimal cut-offs (presepsin > 493 pg/mL and IFN-λ3 > 5.0 pg/mL), the mortality rate was approximately 90% in the elderly patients. Conversely, it was 14.3% in those elderly patients when the level of either one or both biomarkers was below cut-offs. This remarkable difference of mortality rate suggests that the combination of presepsin and IFN-λ3 can be used to stratify the risk of in-hospital mortality even in the same age group, and especially in elderly patients. Previously, the VACO index was developed to stratify the risk of 30-day mortality in same-age groups [8]. One study demonstrated that the combination of procalcitonin, presepsin, and the VACO index predicted 30-day mortality better than the VACO index alone in COVID-19 patients [13]; that finding also suggested that combinations of biomarkers with clinical assessments could be useful to stratify mortality risk in the same age group.
The present study has several limitations. First, it was a small-sized, single center study. We focused on identifying the distributions of each indicator according to the severity of COVID-19 and finding the optimal cut-off for predicting clinical outcomes. Information such as minimum effect size and difference are required to calculate the sample size as well as alpha and power. However, there is insufficient information on the differences between presepsin and IFN-λ3 in COVID-19 cases. Therefore, we used the ROC and Kaplan Meier methods, which are non-parametric survival analyses. Although there was no significant difference in the elderly groups between critical and non-critical diseases, the sample size was small. Therefore, it is necessary to conduct similar studies featuring larger populations to obtain more persuasive and reliable conclusions. Since this was an observational study, confounding variables could be eliminated via various methods such as propensity score matching; however, the sample size was relatively small, so this test was not performed. Therefore, there are limitations in that confounding controls need to be considered. Second, our study was conducted only on adult COVID-19 patients and had a skewed distribution towards the elderly (p = 0.003); accordingly, our data may not be representative of the entire age group. Due to the fact that COVID-19 could cause serious results in children, including multisystem inflammatory syndrome, it is also important to predict disease severity and adverse clinical outcomes in pediatric patients [4]. Third, although the clinical assessment and biomarker testing were conducted simultaneously at time of admission, the heterogeneous disease course of COVID-19 might have affected our data. Fourth, we focused on biomarker levels upon admission without monitoring their sequential changes, which might provide better clinical utility, especially using IVD assays on an automated platform in clinical laboratories. The possibility of using such biomarkers in predicting and stratifying disease severity not only in COVID-19 but also in other diseases should be explored in future studies; furthermore, it would be interesting to evaluate the function of such markers as possible therapeutic targets.
In conclusion, presepsin and IFN-λ3 predicted disease severity and adverse clinical outcomes in hospitalized COVID-19 patients. Both biomarkers, whether assessed alone or added to clinical assessments such as SOFA scores and age, are useful to assess and manage COVID-19 patients, especially the elderly. Further studies are awaited that explore the clinical utility of these novel biomarkers in critically ill patients and that validate our findings.
Author Contributions
G.-H.L. collected samples, analyzed the data, and wrote the draft; M.P., S.L., and H.K. analyzed the data and modified the draft; M.H. conceived the study, analyzed the data, and finalized the draft; H.-W.M. and Y.-M.Y. analyzed and discussed the data. All authors have read and agreed to the published version of the manuscript.
Funding
This work was supported by Konkuk University Medical Center Research Grant 2023.
Institutional Review Board Statement
The study protocol was approved by the institutional review board of KUMC (approval No. 2021-04-048) (17 May 2021).
Informed Consent Statement
Getting written informed consent from the study population was waived.
Data Availability Statement
The data presented in this study are available from the corresponding author on reasonable request.
Conflicts of Interest
The authors report no conflict of interest. The authors alone are responsible for the content and writing of the paper.
References
- World Health Organization. WHO Coronavirus (COVID-19) Dashboard. Available online: https://covid19.who.int/table (accessed on 10 May 2023).
- Tejada-Vera, B.; Kramarow, E.A. COVID-19 mortality in adults aged 65 and over: United States, 2020. NCHS Data Brief. 2022, 446, 1–8. [Google Scholar]
- Yanez, N.D.; Weiss, N.S.; Romand, J.-A.; Treggiari, M.M. COVID-19 mortality risk for older men and women. BMC Public Health 2020, 20, 1742. [Google Scholar] [CrossRef] [PubMed]
- Word Health Organization: Living Guidance for Clinical Management of COVID-19. Available online: https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-2 (accessed on 7 January 2023).
- López-Collazo, E.; Avendaño-Ortiz, J.; Martín-Quirós, A.; Aguirre, L.A. Immune response and COVID-19: A mirror image of sepsis. Int. J. Biol. Sci. 2020, 16, 2479–2489. [Google Scholar] [CrossRef]
- Singer, M.; Deutschman, C.S.; Seymour, C.W.; Shankar-Hari, M.; Annane, D.; Bauer, M.; Bellomo, R.; Bernard, G.R.; Chiche, J.-D.; Coopersmith, C.M.; et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016, 315, 801–810. [Google Scholar] [CrossRef] [PubMed]
- San, I.; Gemcioglu, E.; Baser, S.; Yilmaz Cakmak, N.; Erden, A.; Izdes, S.; Catalbas, R.; Davutoglu, M.; Karabuga, B.; Ates, I. Brescia-COVID Respiratory Severity Scale (BRCSS) and Quick SOFA (qSOFA) score are most useful in showing severity in COVID-19 patients. Sci. Rep. 2021, 11, 21807. [Google Scholar] [CrossRef]
- King, J.T., Jr.; Yoon, J.S.; Bredl, Z.M.; Habboushe, J.P.; Walker, G.A.; Rentsch, C.T.; Tate, J.P.; Kashyap, N.M.; Hintz, R.C., II; Chopra, A.P.; et al. Accuracy of the Veterans Health Administration COVID-19 (VACO) Index for predicting short-term mortality among 1307 US academic medical centre inpatients and 427,224 US Medicare patients. J. Epidemiol. Community Health 2022, 76, 254–260. [Google Scholar] [CrossRef]
- Knight, S.R.; Ho, A.; Pius, R.; Buchan, I.; Carson, G.; Drake, T.M.; Dunning, J.; Fairfield, C.J.; Green, C.A.; Halpin, S.; et al. Risk stratification of patients admitted to hospital with COVID-19 using the ISARIC WHO clinical characterisation protocol: Development and validation of the 4C mortality score. BMJ 2020, 370, m3339. [Google Scholar] [CrossRef]
- Vincent, J.L.; Moreno, R.; Takala, J.; Willatts, S.; De Mendonça, A.; Bruining, H.; Reinhart, C.K.; Suter, P.M.; Thijs, L.G. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the working group on sepsis-related problems of the european society of intensive care medicine. Intensive Care Med. 1996, 22, 707–710. [Google Scholar] [CrossRef]
- Huespe, I.; Carboni Bisso, I.; Di Stefano, S.; Terrasa, S.; Gemelli, N.A.; Las Heras, M. COVID-19 Severity Index: A predictive score for hospitalized patients. Med. Intensiv. (Engl. Ed.) 2022, 46, 98–101. [Google Scholar] [CrossRef]
- Bivona, G.; Agnello, L.; Ciaccio, M. Biomarkers for prognosis and treatment response in COVID-19 patients. Ann. Lab. Med. 2021, 41, 540–548. [Google Scholar] [CrossRef]
- Park, M.; Hur, M.; Kim, H.; Lee, C.H.; Lee, J.H.; Kim, H.W.; Nam, M. Prognostic utility of procalcitonin, presepsin, and the VACO Index for predicting 30-day mortality in hospitalized COVID-19 patients. Ann. Lab. Med. 2022, 42, 406–414. [Google Scholar] [CrossRef] [PubMed]
- Park, M.; Hur, M.; Kim, H.; Lee, C.H.; Lee, J.H.; Nam, M. Usefulness of KL-6 for predicting clinical outcomes in hospitalized COVID-19 patients. Medicina 2022, 58, 1317. [Google Scholar] [CrossRef] [PubMed]
- Ciaccio, M.; Agnello, L. Biochemical biomarkers alterations in Coronavirus Disease 2019 (COVID-19). Diagnosis 2020, 7, 365–372. [Google Scholar] [CrossRef] [PubMed]
- Guarino, M.; Perna, B.; Maritati, M.; Remelli, F.; Trevisan, C.; Spampinato, M.D.; Costanzini, A.; Volpato, S.; Contini, C.; De Giorgio, R. Presepsin levels and COVID-19 severity: A systematic review and meta-analysis. Clin. Exp. Med. 2022. Online ahead of print. [Google Scholar] [CrossRef] [PubMed]
- Assal, H.H.; Abdelrahman, S.M.; Abdelbasset, M.A.; Abdelaziz, M.; Sabry, I.M.; Shaban, M.M. Presepsin as a novel biomarker in predicting in-hospital mortality in patients with COVID-19 pneumonia. Int. J. Infect. Dis. 2022, 118, 155–163. [Google Scholar] [CrossRef]
- Lippi, G.; Sanchis-Gomar, F.; Henry, B.M. Presepsin value predicts the risk of developing severe/critical COVID-19 illness: Results of a pooled analysis. Clin. Chem. Lab. Med. 2022, 60, e1–e3. [Google Scholar] [CrossRef]
- Yang, H.S.; Hur, M.; Yi, A.; Kim, H.; Lee, S.; Kim, S.N. Prognostic value of presepsin in adult patients with sepsis: Systematic review and meta-analysis. PLoS ONE 2018, 13, e0191486. [Google Scholar] [CrossRef]
- Mesev, E.V.; LeDesma, R.A.; Ploss, A. Decoding type I and III interferon signalling during viral infection. Nat. Microbiol. 2019, 4, 914–924. [Google Scholar] [CrossRef]
- Kim, Y.M.; Shin, E.C. Type I and III interferon responses in SARS-CoV-2 infection. Exp. Mol. Med. 2021, 53, 750–760. [Google Scholar] [CrossRef]
- Park, A.; Iwasaki, A. Type I and Type III interferons—Induction, signaling, evasion, and application to combat COVID-19. Cell Host Microbe 2020, 27, 870–878. [Google Scholar] [CrossRef]
- Sugiyama, M.; Kinoshita, N.; Ide, S.; Nomoto, H.; Nakamoto, T.; Saito, S.; Ishikane, M.; Kutsuna, S.; Hayakawa, K.; Hashimoto, M.; et al. Serum CCL17 level becomes a predictive marker to distinguish between mild/moderate and severe/critical disease in patients with COVID-19. Gene 2021, 766, 145145. [Google Scholar] [CrossRef]
- Suzuki, T.; Iwamoto, N.; Tsuzuki, S.; Kakumoto, Y.; Suzuki, M.; Ashida, S.; Oshiro, Y.; Nemoto, T.; Kanda, K.; Okuhama, A.; et al. Interferon lambda 3 in the early phase of coronavirus disease-19 can predict oxygen requirement. Eur. J. Clin. Investig. 2022, 52, e13808. [Google Scholar] [CrossRef]
- Hong, K.H.; Lee, S.W.; Kim, T.S.; Huh, H.J.; Lee, J.; Kim, S.Y.; Park, J.-S.; Kim, G.J.; Sung, H.; Roh, K.H.; et al. Guidelines for laboratory diagnosis of Coronavirus Disease 2019 (COVID-19) in Korea. Ann. Lab. Med. 2020, 40, 351–360. [Google Scholar] [CrossRef]
- Okamura, Y.; Yokoi, H. Development of a point-of-care assay system for measurement of presepsin (sCD14-ST). Clin. Chim. Acta 2011, 412, 2157–2161. [Google Scholar] [CrossRef]
- Kang, T.; Yoo, J.; Choi, H.; Lee, S.; Jekarl, D.W.; Kim, Y. Performance evaluation of presepsin using a Sysmex HISCL-5000 analyzer and determination of reference interval. J. Clin. Lab. Anal. 2022, 36, e24618. [Google Scholar] [CrossRef] [PubMed]
- Sysmex. HISCLTM IFN-λ3 Assay Kit. Available online: https://products.sysmex.co.jp/products/immunology/CN839271/01_index.html (accessed on 7 January 2023).
- Feng, D.; Cortese, G.; Baumgartner, R. A comparison of confidence/credible interval methods for the area under the ROC curve for continuous diagnostic tests with small sample size. Stat. Methods Med. Res. 2017, 26, 2603–2621. [Google Scholar] [CrossRef]
- Simundić, A.M. Diagnostic accuracy. Acta Med. Croat. 2006, 60 (Suppl. S1), 93–111. [Google Scholar]
- Nagashima, K.; Noma, H.; Sato, Y.; Gosho, M. Sample size calculations for single-arm survival studies using transformations of the Kaplan-Meier estimator. Pharm. Stat. 2021, 20, 499–511. [Google Scholar] [CrossRef] [PubMed]
- de Hond, A.A.H.; Steyerberg, E.W.; van Calster, B. Interpreting area under the receiver operating characteristic curve. Lancet Digit. Health 2022, 4, e853–e855. [Google Scholar] [CrossRef] [PubMed]
- Raschke, R.A.; Agarwal, S.; Rangan, P.; Heise, C.W.; Curry, S.C. Discriminant accuracy of the SOFA score for determining the probable mortality of patients with COVID-19 pneumonia requiring mechanical ventilation. JAMA 2021, 325, 1469–1470. [Google Scholar] [CrossRef]
- Lambden, S.; Laterre, P.F.; Levy, M.M.; Francois, B. The SOFA score—Development, utility and challenges of accurate assessment in clinical trials. Crit. Care 2019, 23, 374. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Di Lorenzo, G.; Buonerba, L.; Ingenito, C.; Crocetto, F.; Buonerba, C.; Libroia, A.; Sciarra, A.; Ragone, G.; Sanseverino, R.; Iaccarino, S.; et al. Clinical characteristics of metastatic prostate cancer patients infected with COVID-19 in south Italy. Oncology 2020, 98, 743–747. [Google Scholar] [CrossRef] [PubMed]
Figure 1.
Comparison of presepsin and IFN-λ3 levels between non-critical and critical diseases according to the COVID-19 severity index. (a) Presepsin. (b) Interferon-λ3. Data are presented as median (interquartile range) using horizontal bars. Blue circles represent each individual, red lines represent medians, and black lines represent IQRs.
Figure 1.
Comparison of presepsin and IFN-λ3 levels between non-critical and critical diseases according to the COVID-19 severity index. (a) Presepsin. (b) Interferon-λ3. Data are presented as median (interquartile range) using horizontal bars. Blue circles represent each individual, red lines represent medians, and black lines represent IQRs.
Figure 2.
ROC curve analysis of the SOFA scores, presepsin, IFN-λ3, and age for predicting disease severity according to the COVID-19 severity index (non-critical vs. critical). Abbreviations: ROC, receiver operating characteristic; SOFA, sequential organ failure assessment; IFN-λ3, interferon-λ3; AUC, area under the curve; CI, confidence interval.
Figure 2.
ROC curve analysis of the SOFA scores, presepsin, IFN-λ3, and age for predicting disease severity according to the COVID-19 severity index (non-critical vs. critical). Abbreviations: ROC, receiver operating characteristic; SOFA, sequential organ failure assessment; IFN-λ3, interferon-λ3; AUC, area under the curve; CI, confidence interval.
Figure 3.
ROC curve analysis of the SOFA scores, presepsin, IFN-λ3, and age for predicting adverse clinical outcomes. (a) In-hospital mortality. (b) ICU admission. (c) Ventilator use. (d) Kidney replacement therapy. Abbreviations: see Figure 2; ICU, intensive care unit.
Figure 3.
ROC curve analysis of the SOFA scores, presepsin, IFN-λ3, and age for predicting adverse clinical outcomes. (a) In-hospital mortality. (b) ICU admission. (c) Ventilator use. (d) Kidney replacement therapy. Abbreviations: see Figure 2; ICU, intensive care unit.
Figure 4.
Kaplan-Meier survival analysis of the SOFA scores, presepsin, IFN-λ3, and age for predicting in-hospital mortality. (a) SOFA scores. (b) Presepsin + IFN-λ3. (c) Age. (d) SOFA scores and Presepsin and IFN-λ3. (e) Age and Presepsin and IFN-λ3. Abbreviations: PESP, presepsin; IFN, interferon-λ3; SOFA, sequential organ failure assessment; HR, hazard ratio; CI, confidence interval.
Figure 4.
Kaplan-Meier survival analysis of the SOFA scores, presepsin, IFN-λ3, and age for predicting in-hospital mortality. (a) SOFA scores. (b) Presepsin + IFN-λ3. (c) Age. (d) SOFA scores and Presepsin and IFN-λ3. (e) Age and Presepsin and IFN-λ3. Abbreviations: PESP, presepsin; IFN, interferon-λ3; SOFA, sequential organ failure assessment; HR, hazard ratio; CI, confidence interval.
Table 1.
Demographic, clinical, and laboratory findings of the study population.
| Variable | Total (n = 55) | * Non-Critical (n = 16) | Critical (n = 39) | p |
|---|---|---|---|---|
| Age (years) | 72 (61–80) | 65 (47–75) | 74 (65–82) | 0.023 |
| ≥65, n (%) | 37 (67.3) | 8 (50.0) | 29 (74.4) | 0.115 |
| <65, n (%) | 18 (32.7) | 8 (50.0) | 10 (25.6) | 0.115 |
| Male, n (%) | 30 (54.5) | 7 (43.7) | 23 (59.0) | 0.377 |
| Comorbidities, n (%) | ||||
| At least 2 comorbidities | 28 (50.9) | 5 (31.2) | 23 (59.0) | 0.079 |
| Diabetes mellitus | 20 (36.4) | 5 (31.2) | 15 (38.5) | 0.761 |
| Dementia | 13 (23.6) | 3 (18.8) | 10 (25.6) | 0.734 |
| Heart failure | 7 (12.7) | 0 (0.0) | 7 (17.9) | 0.093 |
| Malignancy | 7 (12.7) | 4 (25.0) | 3 (7.7) | 0.175 |
| Liver disease | 5 (9.1) | 2 (12.5) | 3 (7.7) | 0.622 |
| Chronic obstructive pulmonary disease | 4 (7.3) | 0 (0.0) | 4 (10.3) | 0.311 |
| Chronic kidney disease | 3 (5.5) | 0 (0.0) | 3 (7.7) | 0.548 |
| Cerebrovascular accident | 2 (3.6) | 0 (0.0) | 2 (5.1) | 1.000 |
| Myocardial infarction | 1 (1.8) | 0 (0.0) | 1 (2.6) | 1.000 |
| Chief complaints, n (%) | ||||
| Fever (>37.5 °C) | 23 (41.8) | 8 (50.0) | 15 (38.5) | 0.550 |
| Chill | 10 (18.2) | 1 (6.2) | 9 (23.1) | 0.250 |
| † Respiratory symptoms | 9 (16.4) | 5 (31.2) | 4 (10.3) | 0.103 |
| Dyspnea | 7 (12.7) | 0 (0.0) | 7 (17.9) | 0.093 |
| Headache | 4 (7.3) | 1 (6.2) | 3 (7.7) | 1.000 |
| † Gastrointestinal symptoms | 2 (3.6) | 1 (6.2) | 1 (2.6) | 0.501 |
| ICU stay (day) | 0 (0–14) | 0 (0–0) | 2 (0–16) | 0.024 |
| Hospital stay (day) | 17 (11–31) | 13 (8–25) | 19 (12–37) | 0.045 |
| COVID-19 diagnosis to admission (day) | 0 (0–5) | 0 (0–1) | 0 (0–6) | 0.244 |
| COVID-19 diagnosis to blood sampling (day) | 1 (0–6) | 1 (0–3) | 2 (0–7) | 0.177 |
| Vital signs | ||||
| Mean arterial pressure (mm Hg) | 90 (84–98) | 87 (82–93) | 91 (84–100) | 0.201 |
| Heart rate (frequency/min) | 86 (70–105) | 75 (68–86) | 93 (70–111) | 0.041 |
| Respiratory rate (frequency/min) | 20 (20–22) | 20 (20–20) | 21 (20–25) | 0.005 |
| Body temperature (°C) | 36.7 (36.5–37.6) | 36.5 (36.4–37.6) | 36.8 (36.5–37.6) | 0.190 |
| PaO2/FiO2 (mm Hg) | 377 (309–445) | 460 (374–471) | 358 (285–436) | 0.001 |
| Clinical outcomes | ||||
| ICU admission, n (%) | 23 (41.8) | 3 (18.8) | 20 (51.3) | 0.036 |
| In-hospital mortality, n (%) | 13 (23.6) | 0 (0.0) | 13 (33.3) | 0.011 |
| Ventilator use, n (%) | 11 (20.0) | 0 (0.0) | 11 (28.2) | 0.023 |
| Kidney replacement therapy, n (%) | 5 (9.1) | 0 (0.0) | 5 (12.8) | 0.306 |
| SOFA score | 2 (1–5) | 1 (0–3) | 2 (1–7) | 0.045 |
| Central nervous system | 0 (0–1) | 0 (0–0) | 0 (0–1) | 0.039 |
| Renal | 0 (0–0) | 0 (0–0) | 0 (0–1) | 0.019 |
| Liver | 0 (0–0) | 0 (0–0) | 0 (0–0) | 0.809 |
| Circulatory | 0 (0–0) | 0 (0–0) | 0 (0–1) | 0.189 |
| Coagulation | 0 (0–1) | 0 (0–1) | 0 (0–1) | 0.625 |
| Respiratory | 1 (0–1) | 0 (0–1) | 1 (0–2) | 0.039 |
| Sepsis or septic shock, n (%) | 34 (61.8) | 7 (43.7) | 27 (69.2) | 0.126 |
| Laboratory data | ||||
| White blood cell (×109/L) | 6.4 (4.6–11.3) | 6.3 (4.3–9.5) | 6.6 (4.7–13.9) | 0.535 |
| Neutrophil (×109/L) | 5.2 (3.3–9.9) | 4.1 (2.4–7.9) | 5.5 (3.4–13.2) | 0.258 |
| Lymphocyte (×109/L) | 0.9 (0.6–1.4) | 1.3 (0.9–1.7) | 0.8 (0.5–1.2) | 0.008 |
| Monocyte (×109/L) | 0.4 (0.3–0.7) | 0.4 (0.3–0.6) | 0.4 (0.3–0.8) | 0.767 |
| Red blood cell (×1012/L) | 3.9 (3.5–4.6) | 3.9 (3.6–4.3) | 3.9 (3.4–4.6) | 0.978 |
| Platelet (×109/L) | 186 (143–261) | 179 (149–271) | 188 (136–266) | 0.846 |
| Total bilirubin (umol/L) | 0.6 (0.4–0.9) | 0.6 (0.4–0.8) | 0.6 (0.4–0.9) | 0.493 |
| Blood urea nitrogen (mmol/L) | 17.5 (13.7–27.6) | 12.3 (8.5–17.4) | 18.7 (15.2–35.5) | 0.002 |
| Creatinine (μmol/L) | 0.8 (0.6–1.0) | 0.7 (0.6–0.8) | 0.8 (0.7–1.3) | 0.031 |
| C-reactive protein (mg/L) | 6.2 (2.6–11.7) | 2.8 (0.2–3.5) | 8.0 (3.5–12.3) | 0.004 |
| Presepsin (pg/mL) | 493 (330–963) | 282 (175–579) | 558 (402–1232) | 0.008 |
| Interferon-λ3 (pg/mL) | 3.9 (3.0–12.1) | 3.0 (3.0–3.7) | 6.9 (3.0–13.8) | 0.049 |
| Lactate (mmol/L) | 2.0 (1.8–2.6) | 2.0 (1.4–2.0) | 2.1 (1.8–2.9) | 0.056 |
| Prothrombin time (s) | 13.0 (12.3–14.6) | 12.4 (11.8–13.0) | 13.6 (12.5–15.3) | 0.001 |
| Activated partial thromboplastin time (s) | 39.7 (33.4–44.1) | 33.7 (29.5–39.7) | 40.6 (35.8–45.6) | 0.005 |
| D-dimer (ug/mL) | 1.6 (0.7–3.6) | 1.6 (0.6–3.5) | 1.6 (0.9–3.6) | 0.434 |
Data are expressed as a number (percentage) or median (interquartile range). * The total population was divided into two groups according to the COVID-19 severity index, and non-critical disease includes low (n = 3), moderate (n = 11), and high (n = 2) in the COVID-19 severity index. † Respiratory symptoms include cough, sputum, rhinorrhea, and sore throat; gastrointestinal symptoms include abdominal pain and diarrhea. Abbreviations: SOFA, sequential organ failure assessment; ICU, intensive care unit.
Table 2.
Comparison of in-hospital mortality rate according to the presepsin and interferon-λ3 levels using optimal cut-off values.
Table 2.
Comparison of in-hospital mortality rate according to the presepsin and interferon-λ3 levels using optimal cut-off values.
| PSEP ≤ 493 pg/mL or IFN ≤ 5.0 pg/mL | PSEP > 493 pg/mL and IFN > 5.0 pg/mL | p | |
|---|---|---|---|
| Overall (n = 55) | |||
| Survivor (n = 42) | 40 (95.2) | 2 (4.8) | - |
| Non-survivor (n = 13) | 4 (30.8) | 9 (69.2) | - |
| Mortality rate, proportion (%) | 4/44 (9.1) | 9/11 (81.8) | <0.001 |
| Age ≥ 65 years (n = 37) | |||
| Survivor (n = 25) | 24 (96.0) | 1 (4.0) | - |
| Non-survivor (n = 12) | 4 (33.3) | 8 (66.7) | - |
| Mortality rate, proportion (%) | 4/28 (14.3) | 8/9 (88.9) | <0.001 |
Data are expressed as a number (percentage). The mortality rates were 23.6% (13/55) in the total patients and 32.4% (12/37) in elderly patients (≥65 years). Abbreviations: PESP, presepsin; IFN, interferon-λ3.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Lee, G.-H.; Park, M.; Hur, M.; Kim, H.; Lee, S.; Moon, H.-W.; Yun, Y.-M. Utility of Presepsin and Interferon-λ3 for Predicting Disease Severity and Clinical Outcomes in COVID-19 Patients. Diagnostics 2023, 13, 2372. https://doi.org/10.3390/diagnostics13142372
AMA Style
Lee G-H, Park M, Hur M, Kim H, Lee S, Moon H-W, Yun Y-M. Utility of Presepsin and Interferon-λ3 for Predicting Disease Severity and Clinical Outcomes in COVID-19 Patients. Diagnostics. 2023; 13(14):2372. https://doi.org/10.3390/diagnostics13142372
Chicago/Turabian StyleLee, Gun-Hyuk, Mikyoung Park, Mina Hur, Hanah Kim, Seungho Lee, Hee-Won Moon, and Yeo-Min Yun. 2023. "Utility of Presepsin and Interferon-λ3 for Predicting Disease Severity and Clinical Outcomes in COVID-19 Patients" Diagnostics 13, no. 14: 2372. https://doi.org/10.3390/diagnostics13142372
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
